APO Research
Talk to an analyst

APO RESEARCH · REPORT

KRAS Inhibitor

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

Selected research

Market Analysis & Forecast

Global KRAS Inhibitor Market Analysis and Forecast 2026-2032

25 December 2025193 pages

Choose your research edition.

Industry ResearchKRAS Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS Inhibitor Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal KRAS Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS Inhibitor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

The global KRAS inhibitor market is moving rapidly from an early-launch niche to a scaled targeted-oncology class. Based on APO Research’s estimates, global sales are expected to reach approximately US$0.49 billion in 2024 and grow to around US$3.18 billion by 2032, implying a strong CAGR of about 23–24% over 2025–2032. Growth is volume-driven rather than price-driven: worldwide demand is projected to increase from roughly 8.6 million to more than 78 million 120-mg-equivalent tablets over the same period, while global average net ex-factory prices gradually decline from the high-US$50s per tablet at launch to the low-US$40s by the early 2030s.

Read the full market overview

The market today is highly concentrated in a small number of tumour types and regions. Non-small-cell lung cancer (NSCLC) already accounts for the majority of KRAS inhibitor use, with colorectal cancer forming the second pillar and pancreatic plus other solid tumours contributing a small but fast-growing tail. North America remains the commercial centre of gravity, supported by high testing penetration, rapid reimbursement and comparatively high net prices. Europe scales later and at lower price points but still builds a meaningful second revenue pillar. Asia Pacific is the fastest-growing region: from a negligible base in 2021–2023, volumes expand sharply from 2024 onwards as Japan, South Korea, Australia and, critically, mainland China approve and commercialise KRAS G12C inhibitors. Because domestic products in China are priced materially below US and EU benchmarks, China’s late but rapid entry both reshapes the regional volume mix and pulls down Asia-Pacific average prices.

Competitive intensity is expected to increase as additional first-generation KRAS G12C inhibitors and next-generation molecules targeting other KRAS alleles enter the market. Amgen, Bristol Myers Squibb/Mirati, Innovent Biologics/GenFleet Therapeutics and Jacobio Pharma/Shanghai Allist Pharmaceuticals currently anchor the class, with other multinational and Chinese manufacturers developing follow-on assets. In 2024, the three largest vendors together account for well over 99% of global KRAS inhibitor revenue, but this concentration will moderate as new entrants launch, combination strategies proliferate and regional players consolidate positions in China and other emerging markets.

This report presents an overview of global market for KRAS Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of KRAS Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for KRAS Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the KRAS Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global KRAS Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for KRAS Inhibitor sales, projected growth trends, production technology, application and end-user industry.

KRAS Inhibitor Segment by Company

Amgen

InventisBio/Chia Tai Tianqing Pharmaceutical

Bristol Myers Squibb/Mirati

Innovent Biologics/GenFleet Therapeutics

Jacobio Pharma/Shanghai Allist Pharmaceuticals

KRAS Inhibitor Segment by Type

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Others

KRAS Inhibitor Segment by Application

Clinic Laboratories

Hospitals

Cancer Diagnostic Centres

Others

KRAS Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of KRAS Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, KRAS Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global KRAS Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lung Cancer Major Manufacturers Table 3. Colorectal Cancer Major Manufacturers Table 4. Pancreatic Cancer Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global KRAS Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Clinic Laboratories Major Manufacturers Table 8. Hospitals Major Manufacturers Table 9. Cancer Diagnostic Centres Major Manufacturers Table 10. Others Major Manufacturers Table 11. KRAS Inhibitor Industry Trends Table 12. KRAS Inhibitor Industry Drivers Table 13. KRAS Inhibitor Industry Opportunities and Challenges Table 14. KRAS Inhibitor Industry Restraints Table 15. Global KRAS Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global KRAS Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 17. Global KRAS Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 18. Global KRAS Inhibitor Revenue Market Share by Region (2021-2026) Table 19. Global KRAS Inhibitor Revenue Market Share by Region (2027-2032) Table 20. Global KRAS Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k bottles) Table 21. Global KRAS Inhibitor Sales by Region (2021-2026) & (k bottles) Table 22. Global KRAS Inhibitor Sales by Region (2027-2032) & (k bottles) Table 23. Global KRAS Inhibitor Sales Market Share by Region (2021-2026) Table 24. Global KRAS Inhibitor Sales Market Share by Region (2027-2032) Table 25. Global KRAS Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global KRAS Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 27. Global KRAS Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global KRAS Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 29. Global KRAS Inhibitor Sales Price (USD/bottle) of Manufacturers (2021-2026) Table 30. Global KRAS Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global KRAS Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global KRAS Inhibitor Manufacturers, Product Type & Application Table 33. Global KRAS Inhibitor Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global KRAS Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global KRAS Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 38. Global KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 39. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026) Table 40. Global KRAS Inhibitor Revenue Market Share by Type (2027-2032) Table 41. Global KRAS Inhibitor Sales by Type 2021 VS 2025 VS 2032 (k bottles) Table 42. Global KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 43. Global KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 44. Global KRAS Inhibitor Sales Market Share by Type (2021-2026) Table 45. Global KRAS Inhibitor Sales Market Share by Type (2027-2032) Table 46. Global KRAS Inhibitor Price by Type (2021-2026) & (USD/bottle) Table 47. Global KRAS Inhibitor Price by Type (2027-2032) & (USD/bottle) Table 48. Global KRAS Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 50. Global KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 51. Global KRAS Inhibitor Revenue Market Share by Application (2021-2026) Table 52. Global KRAS Inhibitor Revenue Market Share by Application (2027-2032) Table 53. Global KRAS Inhibitor Sales by Application 2021 VS 2025 VS 2032 (k bottles) Table 54. Global KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 55. Global KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 56. Global KRAS Inhibitor Sales Market Share by Application (2021-2026) Table 57. Global KRAS Inhibitor Sales Market Share by Application (2027-2032) Table 58. Global KRAS Inhibitor Price by Application (2021-2026) & (USD/bottle) Table 59. Global KRAS Inhibitor Price by Application (2027-2032) & (USD/bottle) Table 60. Amgen Company Information Table 61. Amgen Business Overview Table 62. Amgen KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 63. Amgen KRAS Inhibitor Product Portfolio Table 64. Amgen Recent Development Table 65. InventisBio/Chia Tai Tianqing Pharmaceutical Company Information Table 66. InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview Table 67. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 68. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio Table 69. InventisBio/Chia Tai Tianqing Pharmaceutical Recent Development Table 70. Bristol Myers Squibb/Mirati Company Information Table 71. Bristol Myers Squibb/Mirati Business Overview Table 72. Bristol Myers Squibb/Mirati KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 73. Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio Table 74. Bristol Myers Squibb/Mirati Recent Development Table 75. Innovent Biologics/GenFleet Therapeutics Company Information Table 76. Innovent Biologics/GenFleet Therapeutics Business Overview Table 77. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 78. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio Table 79. Innovent Biologics/GenFleet Therapeutics Recent Development Table 80. Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information Table 81. Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview Table 82. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 83. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio Table 84. Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Development Table 85. North America KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 86. North America KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 87. North America KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 88. North America KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 89. North America KRAS Inhibitor Sales Price by Type (2021-2026) & (USD/bottle) Table 90. North America KRAS Inhibitor Sales Price by Type (2027-2032) & (USD/bottle) Table 91. North America KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 92. North America KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 93. North America KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 94. North America KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 95. North America KRAS Inhibitor Sales Price by Application (2021-2026) & (USD/bottle) Table 96. North America KRAS Inhibitor Sales Price by Application (2027-2032) & (USD/bottle) Table 97. North America KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America KRAS Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 99. North America KRAS Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 100. North America KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k bottles) Table 101. North America KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 102. North America KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 103. North America KRAS Inhibitor Sales Price by Country (2021-2026) & (USD/bottle) Table 104. North America KRAS Inhibitor Sales Price by Country (2027-2032) & (USD/bottle) Table 105. United States KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 106. Canada KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 107. Mexico KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 108. Europe KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 109. Europe KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 110. Europe KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 111. Europe KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 112. Europe KRAS Inhibitor Sales Price by Type (2021-2026) & (USD/bottle) Table 113. Europe KRAS Inhibitor Sales Price by Type (2027-2032) & (USD/bottle) Table 114. Europe KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 117. Europe KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 118. Europe KRAS Inhibitor Sales Price by Application (2021-2026) & (USD/bottle) Table 119. Europe KRAS Inhibitor Sales Price by Application (2027-2032) & (USD/bottle) Table 120. Europe KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe KRAS Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 122. Europe KRAS Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 123. Europe KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k bottles) Table 124. Europe KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 125. Europe KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 126. Europe KRAS Inhibitor Sales Price by Country (2021-2026) & (USD/bottle) Table 127. Europe KRAS Inhibitor Sales Price by Country (2027-2032) & (USD/bottle) Table 128. Germany KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 129. France KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 130. U.K. KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 131. Italy KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 132. Russia KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 133. Spain KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 134. Netherlands KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 135. Switzerland KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 136. Sweden KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 137. Poland KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 138. China KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 139. China KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 140. China KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 141. China KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 142. China KRAS Inhibitor Sales Price by Type (2021-2026) & (USD/bottle) Table 143. China KRAS Inhibitor Sales Price by Type (2027-2032) & (USD/bottle) Table 144. China KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 145. China KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 146. China KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 147. China KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 148. China KRAS Inhibitor Sales Price by Application (2021-2026) & (USD/bottle) Table 149. China KRAS Inhibitor Sales Price by Application (2027-2032) & (USD/bottle) Table 150. Asia KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 153. Asia KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 154. Asia KRAS Inhibitor Sales Price by Type (2021-2026) & (USD/bottle) Table 155. Asia KRAS Inhibitor Sales Price by Type (2027-2032) & (USD/bottle) Table 156. Asia KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 157. Asia KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 159. Asia KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 160. Asia KRAS Inhibitor Sales Price by Application (2021-2026) & (USD/bottle) Table 161. Asia KRAS Inhibitor Sales Price by Application (2027-2032) & (USD/bottle) Table 162. Asia KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Asia KRAS Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. Asia KRAS Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. Asia KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k bottles) Table 166. Asia KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 167. Asia KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 168. Asia KRAS Inhibitor Sales Price by Country (2021-2026) & (USD/bottle) Table 169. Asia KRAS Inhibitor Sales Price by Country (2027-2032) & (USD/bottle) Table 170. Japan KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 171. South Korea KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 172. India KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 173. Australia KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 174. Taiwan KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 175. Southeast Asia KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 176. SAMEA KRAS Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA KRAS Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 179. SAMEA KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 180. SAMEA KRAS Inhibitor Sales Price by Type (2021-2026) & (USD/bottle) Table 181. SAMEA KRAS Inhibitor Sales Price by Type (2027-2032) & (USD/bottle) Table 182. SAMEA KRAS Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 183. SAMEA KRAS Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 184. SAMEA KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 185. SAMEA KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 186. SAMEA KRAS Inhibitor Sales Price by Application (2021-2026) & (USD/bottle) Table 187. SAMEA KRAS Inhibitor Sales Price by Application (2027-2032) & (USD/bottle) Table 188. SAMEA KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 189. SAMEA KRAS Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 190. SAMEA KRAS Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 191. SAMEA KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k bottles) Table 192. SAMEA KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 193. SAMEA KRAS Inhibitor Sales by Country (2027-2032) & (k bottles) Table 194. SAMEA KRAS Inhibitor Sales Price by Country (2021-2026) & (USD/bottle) Table 195. SAMEA KRAS Inhibitor Sales Price by Country (2027-2032) & (USD/bottle) Table 196. Brazil KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 197. Argentina KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 198. Chile KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 199. Colombia KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 200. Peru KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 201. Saudi Arabia KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 202. Israel KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 203. UAE KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 204. Turkey KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 205. Iran KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 206. Egypt KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Table 207. Key Raw Materials Table 208. Raw Materials Key Suppliers Table 209. KRAS Inhibitor Distributors List Table 210. KRAS Inhibitor Customers List Table 211. Research Programs/Design for This Report Table 212. Authors List of This Report Table 213. Secondary Sources Table 214. Primary Sources List of Figures Figure 1. KRAS Inhibitor Image Figure 2. Global KRAS Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lung Cancer Image Figure 5. Colorectal Cancer Image Figure 6. Pancreatic Cancer Image Figure 7. Others Image Figure 8. Global KRAS Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global KRAS Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Clinic Laboratories Image Figure 11. Hospitals Image Figure 12. Cancer Diagnostic Centres Image Figure 13. Others Image Figure 14. Global KRAS Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global KRAS Inhibitor Revenue (2021-2032) & (US$ Million) Figure 16. Global KRAS Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global KRAS Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global KRAS Inhibitor Revenue Market Share by Region (2021-2032) Figure 19. Global KRAS Inhibitor Sales (2021-2032) & (k bottles) Figure 20. Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k bottles) Figure 21. Global KRAS Inhibitor Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico KRAS Inhibitor Sales YoY (2021-2032) & (k bottles) Figure 23. Europe KRAS Inhibitor Sales YoY (2021-2032) & (k bottles) Figure 24. China KRAS Inhibitor Sales YoY (2021-2032) & (k bottles) Figure 25. Asia (Excluding China) KRAS Inhibitor Sales YoY (2021-2032) & (k bottles) Figure 26. South America, Middle East and Africa KRAS Inhibitor Sales YoY (2021-2032) & (k bottles) Figure 27. Global KRAS Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global KRAS Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global KRAS Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global KRAS Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global KRAS Inhibitor Revenue Market Share by Type (2021-2032) Figure 33. Global KRAS Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (k bottles) Figure 34. Global KRAS Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global KRAS Inhibitor Sales Market Share by Type (2021-2032) Figure 36. Global KRAS Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global KRAS Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global KRAS Inhibitor Revenue Market Share by Application (2021-2032) Figure 39. Global KRAS Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (k bottles) Figure 40. Global KRAS Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global KRAS Inhibitor Sales Market Share by Application (2021-2032) Figure 42. North America KRAS Inhibitor Revenue Share by Type (2021-2032) Figure 43. North America KRAS Inhibitor Sales Share by Type (2021-2032) Figure 44. North America KRAS Inhibitor Revenue Share by Application (2021-2032) Figure 45. North America KRAS Inhibitor Sales Share by Application (2021-2032) Figure 46. North America KRAS Inhibitor Revenue Share by Country (2021-2032) Figure 47. North America KRAS Inhibitor Sales Share by Country (2021-2032) Figure 48. Europe KRAS Inhibitor Revenue Share by Type (2021-2032) Figure 49. Europe KRAS Inhibitor Sales Share by Type (2021-2032) Figure 50. Europe KRAS Inhibitor Revenue Share by Application (2021-2032) Figure 51. Europe KRAS Inhibitor Sales Share by Application (2021-2032) Figure 52. Europe KRAS Inhibitor Revenue Share by Country (2021-2032) Figure 53. Europe KRAS Inhibitor Sales Share by Country (2021-2032) Figure 54. China KRAS Inhibitor Revenue Share by Type (2021-2032) Figure 55. China KRAS Inhibitor Sales Share by Type (2021-2032) Figure 56. China KRAS Inhibitor Revenue Share by Application (2021-2032) Figure 57. China KRAS Inhibitor Sales Share by Application (2021-2032) Figure 58. Asia KRAS Inhibitor Revenue Share by Type (2021-2032) Figure 59. Asia KRAS Inhibitor Sales Share by Type (2021-2032) Figure 60. Asia KRAS Inhibitor Revenue Share by Application (2021-2032) Figure 61. Asia KRAS Inhibitor Sales Share by Application (2021-2032) Figure 62. Asia KRAS Inhibitor Revenue Share by Country (2021-2032) Figure 63. Asia KRAS Inhibitor Sales Share by Country (2021-2032) Figure 64. SAMEA KRAS Inhibitor Revenue Share by Type (2021-2032) Figure 65. SAMEA KRAS Inhibitor Sales Share by Type (2021-2032) Figure 66. SAMEA KRAS Inhibitor Revenue Share by Application (2021-2032) Figure 67. SAMEA KRAS Inhibitor Sales Share by Application (2021-2032) Figure 68. SAMEA KRAS Inhibitor Revenue Share by Country (2021-2032) Figure 69. SAMEA KRAS Inhibitor Sales Share by Country (2021-2032) Figure 70. KRAS Inhibitor Value Chain Figure 71. Manufacturing Cost Structure Figure 72. KRAS Inhibitor Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others
Applications
  • Clinic Laboratories
  • Hospitals
  • Cancer Diagnostic Centres
  • Others
Companies covered
  • Amgen
  • InventisBio/Chia Tai Tianqing Pharmaceutical
  • Bristol Myers Squibb/Mirati
  • Innovent Biologics/GenFleet Therapeutics
  • Jacobio Pharma/Shanghai Allist Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 KRAS Inhibitor Market by Type
  3. 1.2.1 Global KRAS Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lung Cancer
  5. 1.2.3 Colorectal Cancer
  6. 1.2.4 Pancreatic Cancer
  7. 1.2.5 Others
  8. 1.3 KRAS Inhibitor Market by Application
  9. 1.3.1 Global KRAS Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Clinic Laboratories
  11. 1.3.3 Hospitals
  12. 1.3.4 Cancer Diagnostic Centres
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 KRAS Inhibitor Market Dynamics
  1. 2.1 KRAS Inhibitor Industry Trends
  2. 2.2 KRAS Inhibitor Industry Drivers
  3. 2.3 KRAS Inhibitor Industry Opportunities and Challenges
  4. 2.4 KRAS Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global KRAS Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global KRAS Inhibitor Revenue by Region
  3. 3.2.1 Global KRAS Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global KRAS Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global KRAS Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global KRAS Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global KRAS Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global KRAS Inhibitor Sales by Region
  9. 3.4.1 Global KRAS Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global KRAS Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global KRAS Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global KRAS Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global KRAS Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global KRAS Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global KRAS Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global KRAS Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global KRAS Inhibitor Sales by Manufacturers
  6. 4.2.1 Global KRAS Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global KRAS Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global KRAS Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global KRAS Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global KRAS Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global KRAS Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global KRAS Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global KRAS Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global KRAS Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 KRAS Inhibitor Tier 1, Tier 2, and Tier 3
5 KRAS Inhibitor Market by Type
  1. 5.1 Global KRAS Inhibitor Revenue by Type
  2. 5.1.1 Global KRAS Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global KRAS Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global KRAS Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global KRAS Inhibitor Sales by Type
  6. 5.2.1 Global KRAS Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global KRAS Inhibitor Sales by Type (2021-2032) & (k bottles)
  8. 5.2.3 Global KRAS Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global KRAS Inhibitor Price by Type
6 KRAS Inhibitor Market by Application
  1. 6.1 Global KRAS Inhibitor Revenue by Application
  2. 6.1.1 Global KRAS Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global KRAS Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global KRAS Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global KRAS Inhibitor Sales by Application
  6. 6.2.1 Global KRAS Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global KRAS Inhibitor Sales by Application (2021-2032) & (k bottles)
  8. 6.2.3 Global KRAS Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global KRAS Inhibitor Price by Application
7 Company Profiles
  1. 7.1 Amgen
  2. 7.1.1 Amgen Company Information
  3. 7.1.2 Amgen Business Overview
  4. 7.1.3 Amgen KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Amgen KRAS Inhibitor Product Portfolio
  6. 7.1.5 Amgen Recent Developments
  7. 7.2 InventisBio/Chia Tai Tianqing Pharmaceutical
  8. 7.2.1 InventisBio/Chia Tai Tianqing Pharmaceutical Company Information
  9. 7.2.2 InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview
  10. 7.2.3 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio
  12. 7.2.5 InventisBio/Chia Tai Tianqing Pharmaceutical Recent Developments
  13. 7.3 Bristol Myers Squibb/Mirati
  14. 7.3.1 Bristol Myers Squibb/Mirati Company Information
  15. 7.3.2 Bristol Myers Squibb/Mirati Business Overview
  16. 7.3.3 Bristol Myers Squibb/Mirati KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio
  18. 7.3.5 Bristol Myers Squibb/Mirati Recent Developments
  19. 7.4 Innovent Biologics/GenFleet Therapeutics
  20. 7.4.1 Innovent Biologics/GenFleet Therapeutics Company Information
  21. 7.4.2 Innovent Biologics/GenFleet Therapeutics Business Overview
  22. 7.4.3 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio
  24. 7.4.5 Innovent Biologics/GenFleet Therapeutics Recent Developments
  25. 7.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals
  26. 7.5.1 Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information
  27. 7.5.2 Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview
  28. 7.5.3 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio
  30. 7.5.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America KRAS Inhibitor Market Size by Type
  2. 8.1.1 North America KRAS Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America KRAS Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America KRAS Inhibitor Price by Type (2021-2032)
  5. 8.2 North America KRAS Inhibitor Market Size by Application
  6. 8.2.1 North America KRAS Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America KRAS Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America KRAS Inhibitor Price by Application (2021-2032)
  9. 8.3 North America KRAS Inhibitor Market Size by Country
  10. 8.3.1 North America KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America KRAS Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe KRAS Inhibitor Market Size by Type
  2. 9.1.1 Europe KRAS Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe KRAS Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe KRAS Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe KRAS Inhibitor Market Size by Application
  6. 9.2.1 Europe KRAS Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe KRAS Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe KRAS Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe KRAS Inhibitor Market Size by Country
  10. 9.3.1 Europe KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe KRAS Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China KRAS Inhibitor Market Size by Type
  2. 10.1.1 China KRAS Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China KRAS Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China KRAS Inhibitor Price by Type (2021-2032)
  5. 10.2 China KRAS Inhibitor Market Size by Application
  6. 10.2.1 China KRAS Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China KRAS Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China KRAS Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia KRAS Inhibitor Market Size by Type
  2. 11.1.1 Asia KRAS Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia KRAS Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia KRAS Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia KRAS Inhibitor Market Size by Application
  6. 11.2.1 Asia KRAS Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia KRAS Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia KRAS Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia KRAS Inhibitor Market Size by Country
  10. 11.3.1 Asia KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia KRAS Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA KRAS Inhibitor Market Size by Type
  2. 12.1.1 SAMEA KRAS Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA KRAS Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA KRAS Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA KRAS Inhibitor Market Size by Application
  6. 12.2.1 SAMEA KRAS Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA KRAS Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA KRAS Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA KRAS Inhibitor Market Size by Country
  10. 12.3.1 SAMEA KRAS Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA KRAS Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA KRAS Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 KRAS Inhibitor Value Chain Analysis
  2. 13.1.1 KRAS Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 KRAS Inhibitor Production Mode & Process
  6. 13.2 KRAS Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 KRAS Inhibitor Distributors
  9. 13.2.3 KRAS Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst